Epidemiologic Characteristics, Clinical Behavior, and Outcome of the Giant Cell Tumor of the Bone: A Retrospective Single-center Study | ||
The Archives of Bone and Joint Surgery | ||
مقاله 10، دوره 7، شماره 6، بهمن 2019، صفحه 538-544 اصل مقاله (746.35 K) | ||
نوع مقاله: RESEARCH PAPER | ||
شناسه دیجیتال (DOI): 10.22038/abjs.2018.35070.1924 | ||
نویسندگان | ||
Khodamorad Jamshidi؛ Amin Karimi* ؛ Alireza Mirzaei | ||
Bone and Joint Reconstruction Research Center, Shafa Ortopaedic Hospital, Iran University of Medical Science, Tehran, Iran | ||
چکیده | ||
Background: Giant cell tumor of bone (GCTB) is a locally aggressive lesion with an unpredictable behavior. Herein, the aim of this study was to evaluate the epidemiological characteristics, as well as clinical and functional outcomes of GCTB in a relatively large series of patients. Methods: Patients with the diagnosis of GCTB were included in this retrospective study. Whenever the preservation of the articular surface was possible, surgical options included extended curettage; otherwise, wide resection was implemented. In case of extended curettage, the cavity was filled with cement or bone graft. In addition, the functional and oncologic outcomes of these surgical strategies were compared. The functional outcome of the patients was assessed using the Musculoskeletal Tumor Society (MSTS) scoring system. Results: A total of 120 GCTB patients, including 55 males (45.8%) and 65 females (54.2%), were evaluated. The three involved locations with highest frequency included distal femur (26%), distal radius (22%), and proximal tibia (19%). At a mean follow-up of 125.5±49.2 months, two pulmonary metastases (1.6%) and 12 (10%) local recurrences were observed. In addition, 6 out of 12 (50%) local recurrences occurred in distal radius (P=0.04). The recurrence rate was significantly higher in extended curettage than in wide resection (P=0.05), and the same pattern was observed for allograft, compared to cement filling (P=0.05). The mean MSTS scores for extended curettage and wide resection were 94.7 and 89.1, respectively (P=0.04). Furthermore, the mean MSTS scores for bone graft filling and cement augmentation were obtained as 96 and 93.1, respectively (P=0.07). Conclusion: Based on the findings, wide resection of GCTB was associated with superior oncologic outcome, as well as inferior functional outcome. In extended curettage, cement augmentation resulted in superior oncologic outcome when compared with allograft filling. Level of evidence: IV | ||
کلیدواژهها | ||
Epidemiologic characteristics؛ Functional outcome؛ Giant cell tumor of bone؛ Oncologic outcome | ||
مراجع | ||
1. Cooper A, Travers B. Surgical essays. London: Cox & Son and Longman & Co; 1818. P. 195. 2. Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the surveillance, epidemiology and end results program (1975–2004). Rare Tumors. 2009; 1(2):e52. 3. Jaffe HL. Giant cell tumor of bone: its pathologic appearance, grading, supposed variants and treatment. Arch Pathol. 1940; 30(5):993-1031. 4. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011; 469(2):591-9. 5. Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone-an overview. Arch Bone Jt Surg. 2016; 4(1):2-9. 6. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006; 37(1):35-51. 7. Lopez-Pousa A, Broto JM, Garrido T, Vázquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015; 7(6):419-30. 8. Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015; 9(1):69-74. 9. Campanacci M. Bone and soft tissue tumors. New York: Springer; 2013. 10. Campanacci M. Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases). Recent Results Cancer Res. 1976; 54(1):257-61. 11. Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008; 79(1):86-93. 12. Gupta A, Nath R, Mishra M. Giant cell tumor of bone: multimodal approach. Indian J Orthop. 2007; 41(2):115-20. 13. Dahlin DC, Cupps RE, Johnson EW Jr. Giant‐cell tumor: a study of 195 cases. Cancer. 1970; 25(5):1061-70. 14. Goldenberg RR, Campbell CJ, Bonfiglio M. Giantcell tumor of bone: an analysis of two hundred and eighteen cases. J Bone Joint Surg Am. 1970; 52(4):619-64. 15. Júnior RC, Pereira MG, Garcia PB, Santos PA, Cavalcanti Ados A, Meohas W. Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics. Rev Bras Ortop. 2016; 51(4):459-65. 16. Donthineni R, Boriani L, Ofluoglu O, Bandiera S. Metastatic behaviour of giant cell tumour of the spine. Int Orthop. 2009; 33(2):497-501. 17. Jeys L, Suneja R, Chami G, Grimer R, Carter S, Tillman R. Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop. 2006; 30(2):135-8. 18. Zorlu F, Selek U, Soylemezoglu F, Oge K. Malignant giant cell tumor of the skull base originating from clivus and sphenoid bone. J Neurooncol. 2006; 76(2):149-52. 19. Dahlin DC. Caldwell lecture. Giant cell tumor of bone: highlights of 407 cases. Am J Roentgenol. 1985; 144(5):955-60. 20. O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giantcell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am. 1994; 76(12):1827-33. 21. Teixeira L, Vilela J, Miranda RH, Gomes AH, Costa FA. Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc. 2014; 48(2):136-40. 22. Miszczyk L, Wydmański J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys. 2001; 49(5):1239-42. 23. Dreinhofer K, Rydholm A, Bauer H, Kreicbergs A. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases. J Bone Joint Surg Br. 1995; 77(2):189-93. 24. Cheng DD, Hu T, Zhang HZ, Huang J, Yang QC. Factors affecting the recurrence of giant cell tumor of bone after surgery: A clinicopathological study of 80 cases from a single center. Cell Physiol Biochem. 2015; 36(5):1961-70. 25. Gao ZH, Yin JQ, Xie XB, Zou CY, Huang G, Wang J, et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord. 2014; 15(1):330. 26. Fraquet N, Faizon G, Rosset P, Phillipeau JM, Waast D, Gouin F. Long bones giant cells tumors: treatment by curretage and cavity filling cementation. Orthop Traumatol Surg Res. 2009; 95(6):402-6. 27. Kafchitsas K, Habermann B, Proschek D, Kurth A, Eberhardt C. Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence. Anticancer Res. 2010; 30(9):3795-9. 28. Liu H, Wang J. Treatment of giant cell tumor of bone: a comparison of local curettage and wide resection. Changgeng Yi Xue Za Zhi. 1998; 21(1):37-43. 29. Puri A, Agarwal M. Treatment of giant cell tumor of bone: current concepts. Indian J Orthop. 2007; 41(2):101-8. | ||
آمار تعداد مشاهده مقاله: 500 تعداد دریافت فایل اصل مقاله: 244 |